Skip to main content
Premium Trial:

Request an Annual Quote

Precision Antibody to Develop Monoclonal Antibodies for NCI

NEW YORK (GenomeWeb News) – Precision Antibody said today that it will develop monoclonal antibodies for 20 cancer-related target proteins for a National Cancer Institute program, under an agreement with NCI contractor SAIC-Frederick.

The company will create the standardized, renewable antibodies for the NCI's Clinical Proteomic Technologies for Cancer (CPTC) project, which is focused on increasing the number of monoclonal antibody reagents that are available for clinical cancer proteomics research.

The CPTC is a five-year, $104 million effort to develop new proteomics tools and technologies to accelerate discovery and clinical research, Columbia, Md.-based Precision Antibody said in a statement.

Precision Antibody will develop three monoclonal antibodies against each of 20 cancer-related target antigens made by Argonne National Laboratory and of interest to cancer proteomics researchers.

After Precision Antibody completes its screening and characterization, SAIC-Frederick will undertake screening and additional characterization of antibodies using various techniques, including immuno-mass spectrometry, immunoflourescence, immunoprecipitation, surface plasma resonance, and others.

Final characterization of the antibodies will be conducted by the Biodesign Institute at Arizona State University and the Royal Institute of Technology in Sweden, which runs the Human Protein Atlas.

Financial terms of the agreement were not released.